Literature DB >> 18606421

Idiopathic neuropathy patients are at high risk for metabolic syndrome.

A Gordon Smith1, Kristi Rose, J Robinson Singleton.   

Abstract

BACKGROUND: Idiopathic neuropathy patients are at high risk of impaired glucose tolerance (IGT). Hyperglycemia, low high density lipoprotein (HDL), elevated triglycerides (TRG), hypertension and central obesity co-associate and constitute the metabolic syndrome. Patients with hyperglycemia are at high risk of having the syndrome and each of its features. Our null hypothesis was that patients with neuropathy and IGT would have a higher prevalence of other metabolic syndrome features than those without hyperglycemia. The primary objective was to determine if metabolic syndrome features other than hyperglycemia increase neuropathy risk.
METHODS: The prevalence of metabolic syndrome features was determined among 219 sequential patients with idiopathic peripheral neuropathy. Subjects were classified as having IGT or normoglycemia. The prevalence of metabolic syndrome was compared to published population prevalence data. To compensate for potential referral bias, data were also compared for175 diabetic subjects without neuropathy, given the well-recognized risk of metabolic syndrome among diabetic individuals.
RESULTS: Contrary to our hypothesis, neuropathy patients with normoglycemia and IGT shared a similarly elevated prevalence of metabolic syndrome features compared to published normal populations. Compared to diabetic subjects without neuropathy, the normoglycemic neuropathy patients had significantly higher total and LDL cholesterol, and a higher prevalence of abnormal HDL and triglycerides. The prevalence of obesity and hypertension was similar among patient groups. Normoglycemic neuropathy subjects had significantly more features of metabolic syndrome (other than hyperglycemia) than diabetics.
CONCLUSIONS: These findings demonstrate an association between neuropathy and metabolic syndrome features other than hyperglycemia. Lipid abnormalities are particularly prevalent among neuropathy subjects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606421      PMCID: PMC2576295          DOI: 10.1016/j.jns.2008.06.005

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  20 in total

1.  Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study.

Authors:  J B Meigs; R B D'Agostino; P W Wilson; L A Cupples; D M Nathan; D E Singer
Journal:  Diabetes       Date:  1997-10       Impact factor: 9.461

2.  Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy.

Authors:  J R Singleton; A G Smith; M B Bromberg
Journal:  Diabetes Care       Date:  2001-08       Impact factor: 19.112

3.  Impact of body mass on autonomic function in persons with type 2 diabetes.

Authors:  N Tentolouris; E Grapsas; E Stambulis; K Papageorgiou; N Katsilambros
Journal:  Diabetes Res Clin Pract       Date:  1999-10       Impact factor: 5.602

4.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

Review 5.  Adiponectin: a link between excess adiposity and associated comorbidities?

Authors:  Olavi Ukkola; Merja Santaniemi
Journal:  J Mol Med (Berl)       Date:  2002-09-10       Impact factor: 4.599

6.  Vascular risk factors and diabetic neuropathy.

Authors:  Solomon Tesfaye; Nish Chaturvedi; Simon E M Eaton; John D Ward; Christos Manes; Constantin Ionescu-Tirgoviste; Daniel R Witte; John H Fuller
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

7.  A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy.

Authors:  R A C Hughes; T Umapathi; I A Gray; N A Gregson; M Noori; A S Pannala; A Proteggente; A V Swan
Journal:  Brain       Date:  2004-06-16       Impact factor: 13.501

8.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

Review 9.  Microvascular complications of impaired glucose tolerance.

Authors:  J Robinson Singleton; A Gordon Smith; James W Russell; Eva L Feldman
Journal:  Diabetes       Date:  2003-12       Impact factor: 9.461

10.  Impact of obesity on neuropathic late complications in NIDDM.

Authors:  R H Straub; M Thum; C Hollerbach; K D Palitzsch; J Schölmerich
Journal:  Diabetes Care       Date:  1994-11       Impact factor: 19.112

View more
  45 in total

1.  Small fibre dysfunction, microvascular complications and glycaemic control in type 1 diabetes: a case-control study.

Authors:  P R J Vas; A Q Green; G Rayman
Journal:  Diabetologia       Date:  2011-12-23       Impact factor: 10.122

Review 2.  Drug therapy for chronic idiopathic axonal polyneuropathy.

Authors:  Janna Warendorf; Alexander Fje Vrancken; Ivo N van Schaik; Richard Ac Hughes; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

Review 3.  Neuropathy in prediabetes: does the clock start ticking early?

Authors:  Nikolaos Papanas; Aaron I Vinik; Dan Ziegler
Journal:  Nat Rev Endocrinol       Date:  2011-07-12       Impact factor: 43.330

Review 4.  Neurological consequences of obesity.

Authors:  Phillipe D O'Brien; Lucy M Hinder; Brian C Callaghan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2017-06       Impact factor: 44.182

Review 5.  Relations between metabolic homeostasis, diet, and peripheral afferent neuron biology.

Authors:  Tamara N Dunn; Sean H Adams
Journal:  Adv Nutr       Date:  2014-07-14       Impact factor: 8.701

Review 6.  Chronic idiopathic axonal polyneuropathy: a systematic review.

Authors:  Panagiotis Zis; Ptolemaios Georgios Sarrigiannis; Dasappaiah Ganesh Rao; Channa Hewamadduma; Marios Hadjivassiliou
Journal:  J Neurol       Date:  2016-03-09       Impact factor: 4.849

Review 7.  Mediators of diabetic neuropathy: is hyperglycemia the only culprit?

Authors:  Anna Grisold; Brian C Callaghan; Eva L Feldman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-04       Impact factor: 3.243

8.  Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults : A Prospective Cohort Study.

Authors:  Caitlin W Hicks; Dan Wang; Kunihiro Matsushita; B Gwen Windham; Elizabeth Selvin
Journal:  Ann Intern Med       Date:  2020-12-08       Impact factor: 25.391

Review 9.  Painful and painless diabetic neuropathy: one disease or two?

Authors:  Vincenza Spallone; Carla Greco
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

10.  Neuropathy of impaired glucose tolerance and its measurement.

Authors:  Andrew J M Boulton; Rayaz A Malik
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.